Literature DB >> 12651034

Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.

Stefan K James1, Paul Armstrong, Elliott Barnathan, Robert Califf, Bertil Lindahl, Agneta Siegbahn, Maarten L Simoons, Eric J Topol, Per Venge, Lars Wallentin.   

Abstract

OBJECTIVES: We sought to evaluate C-reactive protein (CRP) and troponin T (TnT) as predictors of risk of the individual end points of mortality and myocardial infarction (MI) in a large cohort of patients with acute coronary syndrome (ACS).
BACKGROUND: Both CRP and TnT predict risk of future coronary events in patients with ACS. However, the relationships between the levels of the markers and the individual end points are still unclear.
METHODS: Baseline levels of CRP and TnT were determined in 7,108 patients with ACS not undergoing early revascularization in the Global Use of Strategies To Open occluded arteries trial IV (GUSTO-IV) trial and related to outcome at 30 days.
RESULTS: Quartiles of TnT related to 30-day mortality, which was 1.1%, 3.7%, 3.7%, and 7.4% (p < 0.001) and to the rate of MI: 2.5%, 6.7%, 7.2%, and 5.6% (p < 0.001). Quartiles of CRP also related to 30-day mortality, which was 2.0%, 3.3%, 3.9%, and 6.3% (p < 0.001), whereas there was no relationship to the 30-day rate of MI: 5.6%, 4.7%, 5.2%, and 5.9% (p = 0.48). On multivariable analysis, both TnT and CRP were independent predictors of mortality, but only TnT was a predictor of MI. The combination of CRP and TnT provides an even better risk stratification of mortality, with 0.3% and 9.1% death rates, respectively, when both markers are in the bottom versus top quartiles.
CONCLUSIONS: In ACS, baseline levels of TnT and CRP are independently related to 30-day mortality. Any detectable elevation of TnT, but not of CRP, is also associated with an increased risk of subsequent MI. Regarding mortality, the combination of both markers provides a better risk stratification than either one alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651034     DOI: 10.1016/s0735-1097(02)02969-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  39 in total

1.  Discordant cardiac biomarker levels independently predict outcome in ST-segment elevation myocardial infarction.

Authors:  Gregor Leibundgut; Michael Gick; Olivier Morel; Miroslaw Ferenc; Klaus-Dieter Werner; Thomas Comberg; Rolf-Peter Kienzle; Heinz Joachim Buettner; Franz-Josef Neumann
Journal:  Clin Res Cardiol       Date:  2015-11-12       Impact factor: 5.460

2.  Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.

Authors:  Benjamin M Scirica; Marc S Sabatine; Petr Jarolim; Sabina A Murphy; James L de Lemos; Eugene Braunwald; David A Morrow
Journal:  Eur Heart J       Date:  2010-12-22       Impact factor: 29.983

3.  Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products.

Authors:  Erick D McNair; Calvin R Wells; A Mabood Qureshi; Rashpal Basran; Colin Pearce; Jason Orvold; Jacobus Devilliers; Kailash Prasad
Journal:  Mol Cell Biochem       Date:  2010-03-27       Impact factor: 3.396

4.  Identification of patients with evolving coronary syndromes by using statistical models with data from the time of presentation.

Authors:  R L Kennedy; R F Harrison
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

Review 5.  [Biomarkers in cardiology--state of the art 2007].

Authors:  Johannes Mair
Journal:  Wien Med Wochenschr       Date:  2007-02

6.  Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials.

Authors:  Jonathan Afilalo; Agnieska A Majdan; Mark J Eisenberg
Journal:  Heart       Date:  2007-02-03       Impact factor: 5.994

7.  Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes.

Authors:  Mary Ann Mascelli; Efthymios N Deliargyris; Lakshmi V Damaraju; Elliot S Barnathan; Robert M Califf; Maarten L Simoons; David C Sane
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

Review 8.  Inflammatory biomarkers and coronary heart disease: from bench to bedside and back.

Authors:  Gina Biasillo; Milena Leo; Roberta Della Bona; Luigi Marzio Biasucci
Journal:  Intern Emerg Med       Date:  2010-02-25       Impact factor: 3.397

9.  Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI.

Authors:  Gert Klug; Agnes Mayr; Johannes Mair; Michael Schocke; Michael Nocker; Thomas Trieb; Werner Jaschke; Otmar Pachinger; Bernhard Metzler
Journal:  Clin Res Cardiol       Date:  2011-01-04       Impact factor: 5.460

10.  Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

Authors:  David A Morrow; Marc S Sabatine; Marie-Luise Brennan; James A de Lemos; Sabina A Murphy; Christian T Ruff; Nader Rifai; Christopher P Cannon; Stanley L Hazen
Journal:  Eur Heart J       Date:  2008-03-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.